Product
Ixekizumab
Aliases
LY2439821, Taltz
Name
TALTZ
INN Name
ixekizumab
FDA Approved
Yes
14 clinical trials
1 organization
22 indications
1 document
Indication
Juvenile Psoriatic ArthritisIndication
Enthesitis Related ArthritisIndication
PsoriasisIndication
Psoriatic ArthritisIndication
Ankylosing spondylitisIndication
HealthyIndication
Psoriasis, GuttateIndication
Type 1 Diabetes MellitusIndication
Major Depressive DisorderIndication
Psoriasis VulgarisIndication
Pyoderma GangrenosumIndication
Rheumatoid ArthritisIndication
SpondyloarthritisIndication
UveitisIndication
posteriorIndication
AnteriorIndication
IntermediateIndication
PanuveitisIndication
Lichen Planus ScalpIndication
Lichen PlanusIndication
Lichen PlanopilarisIndication
Atopic DermatitisClinical trial
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisStatus: Active (not recruiting), Estimated PCD: 2024-02-19
Clinical trial
A 24-Week Multicenter, Open-label, Single-arm, Phase 4 Study to Evaluate the Safety of Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis or Active Psoriatic Arthritis in IndiaStatus: Active (not recruiting), Estimated PCD: 2024-07-17
Clinical trial
A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial SpondyloarthritisStatus: Completed, Estimated PCD: 2021-03-31
Clinical trial
A Randomized Study to Investigate Injection-Site Pain Following Subcutaneous Injections of 2 Ixekizumab Test Formulations Compared to the Commercial Formulation Using a Pre-filled Syringe in Healthy SubjectsStatus: Terminated, Estimated PCD: 2019-07-18
Clinical trial
Efficacy and Safety of Ixekizumab in Patients With Refractory Guttate PsoriasisStatus: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
The Effect of Anti-IL17 in New-onset Type 1 Diabetes: a Randomized, Double-blind, Placebo-controlled TrialStatus: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
An Experimental Therapeutics Study of a Monoclonal Antibody Against Interleukin 17A in Patients With Treatment-Resistant DepressionStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio StudyStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumStatus: Completed, Estimated PCD: 2018-08-16
Clinical trial
The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Influence of Temporary Interruptions in Immunomodulatory TherapyStatus: Recruiting, Estimated PCD: 2024-02-29
Clinical trial
A 24-week Two-armed Proof-of-concept Exploratory Analysis of Subcutaneous Ixekizumab Administration in Patients With Recalcitrant Non-infectious Intermediate, Posterior, Panuveitis, or Chronic Steroid-dependent Anterior Uveitis.Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Proactive Therapeutic Drug Monitoring Versus Routine Care With the Novel Biologics in Psoriasis : a Pragmatic, Multicentric, Randomised, Controlled StudyStatus: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Proof of Concept, Non-randomized, One Center Study to Explore the Safety and Efficacy of 16 Weeks of Treatment With Ixekizumab in Adult Patients With Lichen Planus and Lichen PlanopilarisStatus: Completed, Estimated PCD: 2024-03-25
Clinical trial
Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin DisordersStatus: Recruiting, Estimated PCD: 2027-12-31
Document
DailyMed Label: TALTZOrganization
Eli Lilly and Company